IDEXX Q3 FY2026: revenue up 9.9%, EPS $4.01, outlook raised
IDEXX beat on both lines and raised 2026 guidance, so the quarter reads as a clean operating win: revenue of $1.214 billion, EPS of $4.01 against a $3.81 consensus, and a full-year revenue target lifted by $32 million at the midpoint. Read that raise next to a trimmed operating margin outlook — more sales, slightly thinner profit per dollar. The view is Bullish.
1 · Expected vs. Actual
Free preview belowDiluted EPS of $4.01 beat the $3.81 consensus and rose 18% from $3.40; on a comparable basis EPS was $3.96, up 22%. Management flagged $0.04 per share of currency help and $0.03 from a non-operating equity gain, so the beat is mostly operating rather than one-off.
Revenue was $1.214 billion, up 9.9% from $1.105 billion a year earlier, with CAG Diagnostics recurring revenue up 11.0% as reported and organic. VetLab consumables did the heavy lifting at 14.3% reported growth, while rapid assay products managed only 0.6% as lower testing volumes offset price.
Full-year revenue guidance rose to $4,741–$4,767 million, a midpoint of $4.754 billion, and EPS guidance rose to $14.96–$15.16, a $0.25 lift at the midpoint. The catch is margin: the operating margin outlook was cut to 32.1%–32.3% from 32.3%–32.5%, so the extra revenue arrives with slightly less profit per dollar.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-02
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.